Capital World Investors Bio N Tech Se Transaction History

Capital World Investors

$625 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $1.03 Million - $1.32 Million	12,863 Added 1.36%	955,979 $76.8 Million
Q1 2024 May 14, 2024	BUY	$88.96 - $112.35 $388,666 - $490,857	4,369 Added 0.47%	943,116 $87 Million
Q4 2023 Feb 13, 2024	BUY	$90.91 - $112.75 $1.28 Million - $1.58 Million	14,027 Added 1.52%	938,747 $99.1 Million
Q3 2023 Nov 13, 2023	BUY	$98.5 - $125.08 $3,940 - $5,003	40 Added 0.0%	924,720 $100 Million
Q2 2023 Aug 11, 2023	SELL	$102.58 - $129.66 $47.8 Million - $60.4 Million	-466,048 Reduced 33.51%	924,680 $99.8 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $83 Million - $104 Million	-677,520 Reduced 32.76%	1,390,728 $173 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $52.5 Million - $82.5 Million	443,586 Added 27.3%	2,068,248 $311 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $112 Million - $161 Million	880,179 Added 118.23%	1,624,662 $219 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $19,843 - $29,984	161 Added 0.02%	744,483 $111 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $145 Million - $267 Million	-1,152,076 Reduced 60.75%	744,322 $127 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $220 Million - $368 Million	-1,014,544 Reduced 34.85%	1,896,398 $489 Million
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $102 Million - $222 Million	-495,408 Reduced 14.54%	2,910,942 $795 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $337 Million - $718 Million	2,973,468 Added 686.9%	3,406,350 $763 Million
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $37.1 Million - $51.7 Million	432,882 New	432,882 $47.3 Million

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account